- Home
- KZIA vs AZTR Comparison
KZIA vs AZTR Comparison
Compare KZIA & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- AZTR
- Stock Information
- Founded
- KZIA 1994
- AZTR 2014
- Country
- KZIA Australia
- AZTR United States
- Employees
- KZIA N/A
- AZTR 12
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- AZTR Health Care
- Exchange
- KZIA Nasdaq
- AZTR Nasdaq
- Market Cap
- KZIA 5.1M
- AZTR 4.0M
- IPO Year
- KZIA 1999
- AZTR 2023
- Fundamental
- Price
- KZIA $6.10
- AZTR $0.26
- Analyst Decision
- KZIA Strong Buy
- AZTR
- Analyst Count
- KZIA 2
- AZTR 0
- Target Price
- KZIA $57.50
- AZTR N/A
- AVG Volume (30 Days)
- KZIA 2.6M
- AZTR 4.6M
- Earning Date
- KZIA 07-07-2025
- AZTR 08-11-2025
- Dividend Yield
- KZIA N/A
- AZTR N/A
- EPS Growth
- KZIA N/A
- AZTR N/A
- EPS
- KZIA N/A
- AZTR N/A
- Revenue
- KZIA $1,549,158.00
- AZTR $7,500.00
- Revenue This Year
- KZIA N/A
- AZTR N/A
- Revenue Next Year
- KZIA N/A
- AZTR N/A
- P/E Ratio
- KZIA N/A
- AZTR N/A
- Revenue Growth
- KZIA 248983.08
- AZTR N/A
- 52 Week Low
- KZIA $2.86
- AZTR $0.23
- 52 Week High
- KZIA $79.00
- AZTR $12.00
- Technical
- Relative Strength Index (RSI)
- KZIA 50.96
- AZTR 46.07
- Support Level
- KZIA $5.83
- AZTR $0.23
- Resistance Level
- KZIA $9.60
- AZTR $0.36
- Average True Range (ATR)
- KZIA 1.19
- AZTR 0.02
- MACD
- KZIA -0.29
- AZTR -0.00
- Stochastic Oscillator
- KZIA 18.39
- AZTR 26.79
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.